The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Johanna C. Bendell*, Tamara Sauri, Antonio Cubillo Gracian, Rafael Alvarez, Carols Lopez-Lopez, Pilar Garcia-Alfonso, Maen Hussein, Maria-Luisa Limon Miron, Andres Cervantes, Clara Montagut, Cristina Santos Vivas, Alberto Bessudo, Patrica Plezia, Veerle Moons, Johannes Andel, Jafaar Bennouna, Andre van der Westhuizen, Leslie Samuel, Simona Rossomanno, Christophe BoetschAngelika Lahr, Izolda Franjkovic, Florian Heil, Katharina Lechner, Oliver Krieter, Herbert Hurwitz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)
2 Downloads (Pure)

Fingerprint

Dive into the research topics of 'The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)'. Together they form a unique fingerprint.

Medicine & Life Sciences